Not every CRO that says MedTech means it. The distinction between a device-first CRO and a pharma CRO that has added a device practice is real, and it shows in the work. Many generalist CROs learned device pathways as a second language, regulatory teams trained in drug development who adapted to devices as the market demanded. That gap is invisible until it isn’t.
It shows how the regulatory strategy is built, how the protocol accounts for device-specific endpoints, and whether the team has actually run IDE studies and EU MDR clinical investigations or just advised on them. It shows whether PMCF is treated as a post-market obligation or designed into the evidence strategy from day one.
This guide covers how to evaluate that difference: what to ask, what to watch for, and how to apply a consistent framework across every CRO you consider.
What is a MedTech CRO?
A contract research organization (CRO) is an external partner that provides clinical, regulatory, and operational services to sponsors developing medical products. A MedTech CRO is one that specializes specifically in medical devices, diagnostics, combination products, and digital health, as distinct from pharma-first CROs that have added device capabilities as a secondary offering.
The distinction matters.
Medical device development operates under a fundamentally different regulatory framework from pharmaceutical development. Device trials are designed around procedural performance, operator technique, real-world usability, and device-specific endpoints rather than pharmacokinetics or dose response. Unlike drug trials, which follow relatively standardized protocols adapted to phase and indication, device trials are inherently custom. Each one is shaped by the specific device, its mechanism of action, the disease state it targets, and the clinical context in which it will be used. There is no universal playbook. Regulatory pathways vary significantly by geography and device classification. In the US, these include FDA IDE, 510(k), De Novo, and PMA. In Europe, EU MDR and IVDR. And across other markets, a range of regional frameworks each with distinct submission requirements, timelines, and evidence standards. Generalist CROs frequently underestimate the depth of expertise each pathway demands.
A true MedTech CRO integrates clinical operations, regulatory strategy, and engineering expertise into a single delivery model. For sponsors evaluating options, the question is not just which CRO has the capacity but which one has the depth and expertise embedded to serve as a genuine strategic partner throughout the program.
Key selection criteria for a MedTech CRO
Not all CROs are created equal, and in MedTech, the gaps between strong and weak partners are consequential. The following criteria should anchor your evaluation.
MedTech specialization, not generalist coverage. The CRO should have a demonstrated track record in medical device and diagnostic development, not just listed capabilities. Look for evidence of device-specific regulatory submissions, clinical trial experience across device categories, and a team with device backgrounds rather than pharma backgrounds.
Regulatory depth across multiple pathways. Your CRO should be fluent across the regulatory frameworks relevant to your program and your target markets. That may include FDA IDE, 510(k), De Novo, and PMA in the US; EU MDR and IVDR clinical investigation requirements in Europe; PMCF obligations post-approval; and regional frameworks in APAC, LATAM, or other markets depending on your commercialization strategy. A CRO that only knows one regulatory environment is not built for a global program.
Integrated advisory and clinical capability. The strongest MedTech CROs integrate advisory services (regulatory strategy, market access, quality, and engineering) directly with clinical operations. This integration is what allows a CRO to do more than execute a protocol: it can help you design one that generates evidence strong enough to support both regulatory approval and commercial adoption.
The right question to ask is whether your clinical development partner and your regulatory and market access advisors share the same knowledge base. If they don’t, you’re paying to brief multiple vendors on the same program.
Global site network with local expertise. If your program requires multi-geography execution, or if you anticipate needing EU, US, or Asia-Pacific submissions, verify that the CRO has an established site network and local regulatory knowledge. A global footprint on paper is not the same as in-country execution capability.
Therapeutic area experience. MedTech spans cardiovascular, neurology, orthopedics, diagnostics, digital health, aesthetics, oncology, and more. A CRO that has run cardiovascular IDE studies may not have the same depth in IVD diagnostic validation or SaMD regulatory strategy. Verify specific experience in your device category and study type, not just the broader service line.
Engagement model flexibility. Some sponsors need a full-service CRO to own the program end to end. Others need FSP support to augment an established internal team. A strong partner can operate across both models and help you determine which structure fits your program rather than defaulting to the model that generates more revenue for them.
Transparent communication and sponsor visibility. Ask how the CRO handles delays, protocol deviations, and scope changes. Strong partners communicate proactively; weaker ones surface problems late. Request references from sponsors with complex or troubled programs, not just clean, straightforward studies.
Red flags to watch for
The following patterns have appeared repeatedly in sponsors’ post-mortem accounts of failed or underperforming CRO relationships. Treat each one as a signal worth investigating before signing.
- No dedicated MedTech team. Device work is handled by the pharma clinical team with some adaptation. Ask specifically who will staff your program, not just who is listed on the capabilities page.
- Regulatory expertise is subcontracted. If the CRO cannot name in-house regulatory personnel with device submission experience, the regulatory function is likely a referral, not a core competency.
- Template-based proposals with no evidence of program-specific thinking. A strong CRO should be able to identify the likely protocol design challenges for your specific device and study type before a contract is signed.
- Vague answers on site activation timelines. Site selection and activation is one of the most common sources of delay in device trials. Any CRO that cannot be specific about its site network and activation track record in your geography should be pressed harder.
- No fluency in your specific regulatory pathway. If you are running a pivotal EU MDR clinical investigation and the CRO’s regulatory team is primarily FDA-focused, that is a material risk and not a gap to close after contracting.
- Overselling on scope without asking enough questions. A CRO that quotes confidently on a complex program without thoroughly interrogating your device, indication, study design, and regulatory history has likely defaulted to a template rather than engaging with your actual situation.
- References that are all positive and all straightforward. Ask for references from programs that hit complications. How a CRO navigates adversity is more informative than how it performs when everything goes to plan.
Questions to ask before you sign
Use these questions in your CRO evaluation conversations. Strong partners will have specific, substantiated answers. Weak ones will generalize.
- How many medical device clinical trials has your team run in the past three years, and in what therapeutic areas?
- Can you walk us through a recent program in our device category where the study design required adjustment after protocol finalization?
- What is your process when a site is underenrolling or a protocol deviation is identified mid-study?
- Do you have in-house regulatory expertise for [FDA IDE / EU MDR clinical investigation / IVDR / relevant pathway], or do you subcontract that function?
- How do you structure the engagement if our program requires both advisory support (regulatory strategy, market access) and clinical execution?
- What does your FSP model look like, and under what circumstances would you recommend it over full-service engagement?
- Can we speak with a sponsor whose program experienced a significant complication and how you supported them through it?
CRO selection checklist
Use this checklist when comparing two or more CROs side by side. Rate each criterion for each candidate (meets / partially meets / does not meet) and weight according to your program priorities.
- MedTech-exclusive or MedTech-primary focus (not pharma-first with device add-on)
- Demonstrated device regulatory experience: in-house, not subcontracted
- Specific therapeutic area experience in your device category and study type
- Regulatory pathway fluency: FDA IDE, 510(k) / De Novo / PMA, EU MDR, IVDR (as applicable)
- Integrated advisory capability: regulatory strategy, market access, reimbursement, cybersecurity, digital health, quality, and engineering
- Full-service and FSP engagement model flexibility
- Established global site network Established global site network with in-country medical device trial experience in your required geographies, not just site volume
- Transparent communication protocols: escalation process, deviation handling, scope change management
- Strong references from programs with complications, not just straightforward studies
- Cultural fit: does the team engage as a partner or as a vendor?
What makes Avania different
Avania is the premier global CRO built exclusively for MedTech. With 1,100+ discrete projects, 500+ global regulatory submissions, 600+ Medical Device & Diagnostic trials, 40+ countries, 6 continents and 60+ Breakthroughs and Accelerated Designations, Avania brings the scale of a global partner and the focus of a MedTech specialist.
Unlike pharma-first CROs that have added device capabilities over time, Avania’s entire team (clinical, regulatory, engineering, and market access) is organized around the specific requirements of medical device and diagnostic development. Advisory services and clinical development are integrated into a single delivery model, so regulatory strategy, protocol design, and evidence planning are aligned from the start of a program.
Avania supports both full-service engagement and FSP partnerships, and works with sponsors to determine which structure best fits their program, their team, and their timeline.
Don’t sign without a champion in your corner.
Frequently asked questions
What is a MedTech CRO and how is it different from a pharma CRO?
A MedTech CRO is a contract research organization that specializes in medical device, diagnostic, combination product, and digital health development. Unlike pharma-first CROs, a MedTech CRO is structured around device-specific regulatory pathways (IDE, 510(k), De Novo, PMA, EU MDR) and clinical trial designs that account for procedural performance, operator variability, and real-world device use. Generalist CROs frequently apply pharmaceutical frameworks to device programs, which creates misalignment in protocol design, endpoint selection, and regulatory strategy. A dedicated MedTech CRO brings device-native expertise across clinical, regulatory, engineering, and commercial functions.
How much does it cost to hire a MedTech CRO?
CRO cost for a medical device program varies widely based on study type, number of sites, geographic scope, device complexity, regulatory pathway, and engagement model (full-service vs. FSP). Early feasibility studies are substantially less expensive than global pivotal trials. FSP engagements are typically structured on a time-and-materials or functional unit basis and can offer more granular cost control than bundled full-service contracts. The most accurate way to understand cost is through a scoping conversation that accounts for your specific program, timeline, and regulatory requirements.
It’s also worth considering the alternative. Building an internal cross-disciplinary team with regulatory, clinical, and engineering expertise requires significant fixed overhead regardless of program phase. A CRO that scales with your needs can be more cost-effective across the full MedTech product lifecycle.
How long does it take to select a MedTech CRO?
A thorough CRO selection process typically takes four to twelve weeks, depending on the number of CROs in consideration, the complexity of the program, and the depth of the due diligence process. Early-stage programs with straightforward scope can move faster. Complex, global, or multi-phase programs benefit from a more thorough evaluation, including reference checks, site network verification, and regulatory capability review. Starting the selection process earlier than you think you need to is consistently better advice than starting when urgency is already high.
Can a MedTech CRO also help with regulatory strategy?
Yes. The strongest MedTech CROs integrate regulatory strategy directly into clinical development rather than treating them as separate workstreams. At Avania, advisory services including regulatory strategy, market access, quality, and engineering are embedded alongside clinical trial execution, which means regulatory considerations inform protocol design, endpoint selection, and evidence planning from the start. This integration helps avoid the common problem of running a trial that generates data unsuitable for the intended submission pathway.
What should I look for in a CRO for a first-in-human or early feasibility study?
For a first-in-human (FIH) or early feasibility study (EFS), prioritize regulatory depth and regional operational expertise over operational scale. The most important factors are: in-house regulatory expertise for your specific pathway (FDA IDE or equivalent), experience designing FIH protocols for your device category, a strong safety monitoring infrastructure, and the ability to integrate clinical and regulatory planning so early study data supports your eventual pivotal strategy. Early-phase programs are where the evidence foundation is laid. A CRO that executes well but does not understand the downstream regulatory implications of your protocol design can create problems that are expensive to fix later.
For FIH specifically, also look for a CRO with flexible operating procedures that can accommodate mid-study design changes without significant disruption, and established relationships with KOLs and centers of excellence who have experience executing first-in-human device studies.